AKT1 and Parkinson disease: In addition, in MPP+-treated BV-2 cells and primary microglia, fingolimod significantly decreased the phosphorylation level of PI3/K/Akt/GSK3 β signalling pathway, ROS production, and p65 phosphorylation by inhibiting NLRP3 inflammatory bodies, suggesting that fingolimod may be a strategy against PD [189].